Evidence map›Paper›PMID 28033507›Full record

ArticleNeurobiology of aging2017

Regulatory region genetic variation is associated with FYN expression in Alzheimer's disease.

Jeffrey A Zahratka, Yvonne Shao, McKenzie Shaw, Kaitlin Todd, Shane V Formica, Maria Khrestian, Thomas Montine, James B Leverenz, Lynn M Bekris

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurobiology of aging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jeffrey A ZahratkaGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: zahratj@ccf.org.
Yvonne ShaoGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
McKenzie ShawGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Kaitlin ToddGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Shane V FormicaGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Maria KhrestianGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Thomas MontineDepartment of Pathology, Stanford University, Palo Alto, CA, USA.
James B LeverenzLou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA.
Lynn M BekrisGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Cleveland Clinic · USPalo Alto University · US

Funding

THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI WIJSMAN, ELLEN M · 1985 to 2019
$57.2M
Biomarker Expression and Regulatory Haplotypes in Alzheimer's DiseaseR00AG034214 · NIA · UNIVERSITY OF WASHINGTON · PI BEKRIS, LYNN · 2012 to 2014
$725k
Biomarker Expression and Regulatory Haplotypes in Alzheimer's DiseaseK99AG034214 · NIA · UNIVERSITY OF WASHINGTON · PI BEKRIS, LYNN · 2010 to 2011
$254k
NIA NIH HHS K99 AG034214NIA NIH HHS P50 AG005136NIA NIH HHS R00 AG034214
6 · The paper itself

Abstract

Neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau, are a key pathologic feature of Alzheimer's disease (AD). Tau phosphorylation is under the control of multiple kinases and phosphatases, including Fyn. Previously, our group found an association between 2 regulatory single nucleotide polymorphisms in the FYN gene with increased tau levels in the cerebrospinal fluid. In this study, we hypothesized that Fyn expression in the brain is influenced by AD status and genetic content. We found that Fyn protein, but not messenger RNA, levels were increased in AD patients compared to cognitively normal controls and are associated with regulatory region single nucleotide polymorphisms. In addition, the expression of the FYN 3'UTR can decrease expression in multiple cell lines, suggesting this regulatory region plays an important role in FYN expression. Taken together, these data suggest that FYN expression is regulated according to AD status and regulatory region haplotype, and genetic variants may be instrumental in the development of neurofibrillary tangles in AD and other tauopathies.

Indexed as

Genetic Association Studies3' Untranslated RegionsAgedAged, 80 and overAlzheimer DiseaseBrainCell LineFemaleGene ExpressionGenetic VariationHaplotypesHumansMalePhosphorylationPolymorphism, Single NucleotideProto-Oncogene Proteins c-fyn3' Untranslated RegionsFYN protein, humanProto-Oncogene Proteins c-fyntau ProteinsAlzheimer's diseaseCerebellumFynHippocampusReporter assaySNP

Identifiers

PMID28033507
PMCPMC5358011
OpenAlexW2556244399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.